Background Although the docetaxel, 5-fluorouracil, and cisplatin triplet has yielded significant improvements in time to progression, overall survival, and overall response rate, the high incidence of severe adverse events limits the use of the docetaxel, 5-fluorouracil, and cisplatin triplet. To overcome this limitation, we evaluated the efficacy and safety of the combination of docetaxel, oxaliplatin, and S-1 for the treatment of metastatic gastric cancer. Methods Chemotherapy-naive patients with pathologically proven unresectable recurrent or metastatic gastric adenocarcinoma were assessed for eligibility. Docetaxel at 52.5 mg/m 2 and oxaliplatin at 105 mg/m 2 were administered intravenously on day 1, and S-1 was administered orally at 80 mg/m 2 on days 1-14 of every 21-day cycle.
Introduction
Gastric cancer is the third commonest cause of cancer-driven death worldwide [1] . Many patients present initially with locally advanced disease or distant metastases, and a considerable number of patients develop recurrence even after complete resection [2] . For these patients, combination chemotherapy has been shown to improve the quality of life and overall survival (OS) compared with best supportive care alone [3] . Although a standard front-line chemotherapy regimen for advanced gastric cancer (AGC) has not yet been established, the combination of epirubicin, cisplatin or oxaliplatin, and fluoropyrimidine has been considered a reference regimen in Europe. In other regions, platinum and fluoropyrimidine doublets have been adopted as a reference regimen in clinical trials. In a phase III trial, the docetaxel, 5-fluorouracil (5-FU), and cisplatin (DCF) triplet yielded significant improvements in time to progression (TTP), OS, and overall response rate (ORR) compared with the cisplatin and 5-FU doublet in AGC [4] . Nevertheless, the high incidence of severe adverse events such as febrile neutropenia and infection and the inconvenience of continuous intravenous 5-FU infusion limit the use of this regimen worldwide as a popular chemotherapeutic regimen. Docetaxel is an active agent for treating patients with gastric cancer, with ORRs of 16-24 % as a single agent [5] [6] [7] and 19-37 % in combination with 5-FU and/or cisplatin [4, 8, 9] . Oxaliplatin is a platinum analog with less nephrotoxicity than cisplatin, and its efficacy is not inferior to that of cisplatin in the treatment of AGC [10, 11] . S-1, an oral 5-FU prodrug, is active against AGC as a single agent or in combination with cisplatin in phase III trials. These trials suggest that S-1 was not inferior to 5-FU, with less toxicity, and can replace 5-FU for the treatment of AGC [12, 13] . The rationale for the combination of docetaxel, oxaliplatin, and S-1 (DOS) is that each agent is active against gastric cancer with a distinct mechanism of action and the principal toxicities of these drugs are different: neutropenia is the principal toxicity of docetaxel, neuropathy is the major toxicity of oxaliplatin, and gastrointestinal toxicity is the main side effect of S-1.
Considering the evident efficacies and more favorable toxicity profiles in addition to the more convenient administration of oxaliplatin and S-1 (SOX) compared with cisplatin and infusional 5-FU, the DOS regimen was expected to be better tolerated, more convenient, and more effective than previously used therapies. We performed a dose-finding study using the DOS regimen [14] . The doselimiting toxicity was neutropenia, and the ORR was 67 %. The recommended DOS chemotherapy in patients with AGC was docetaxel at 52.5 mg/m 2 and oxaliplatin at 105 mg/m 2 on day 1, and S-1 at 80 mg/m 2 on days 1-14 of every 21-day cycle.
Therefore, we conducted a phase II study to investigate the efficacy and feasibility of the DOS regimen in patients with AGC.
Patients and methods

Study design
This trial was a single-arm phase II study evaluating combination chemotherapy with DOS. The primary end point was ORR, and the secondary end points were OS, progression-free survival (PFS), and assessment of toxicity.
The investigation was performed in accordance with the Declaration of Helsinki, and the protocol was approved by the institutional review boards of Hallym University Medical Center, Anyang, South Korea and Asan Medical Center, Seoul, South Korea.
Eligibility
Patients with pathologically proven unresectable recurrent or metastatic gastric adenocarcinoma were assessed for eligibility. The major inclusion criteria were as follows: measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 [15] ; age 18-70 years; an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-2; adequate bone marrow function (defined by a leukocyte count of 4000/lL or greater, an absolute neutrophil count of 1500/lL or greater, a platelet count of 100,000/lL or greater, and a serum hemoglobin level of 9 g/dL or greater); adequate renal function (serum creatinine level below 1.5 mg/dL); and adequate hepatic function (bilirubin level below 2.0 mg/dL, and aspartate aminotransferase and alanine aminotransferase levels twofold or less of the reference value). Prior radiotherapy was permitted if it was not administered to the target lesions evaluated in this study and if it had been completed at least 4 weeks before enrollment of the patient into the study.
Patients in whom adjuvant chemotherapy had been completed at least 6 months before recruitment were enrolled. However, patients with recurrence after adjuvant S-1-, oxaliplatin-, or docetaxel-based chemotherapy were not eligible for the study regardless of the time to recurrence. Patients with brain metastasis, obvious bowel obstruction, or serious gastrointestinal bleeding were excluded. Each patient provided written informed consent before study enrollment.
Pretreatment evaluations
Baseline evaluations included confirmation of the pathologic diagnosis, medical history, physical examination, ECOG PS, complete blood count, serum chemistry and electrolytes, urine analysis, chest X-ray, and three-dimensional computed tomography.
Treatment schedule
The treatment consisted of intravenous administration of docetaxel (Taxotere 2 or more but less than 1.5 m 2 received 100 mg S-1 daily, and those with a body surface area of 1.5 m 2 or more received 120 mg S-1 daily. Prophylactic dexamethasone was prescribed to prevent potential hypersensitivity reactions to docetaxel. The treatment was repeated every 3 weeks until there was disease progression or unacceptable toxicity or the patient withdrew consent. Standard antiemetic prophylaxis by intravenously or orally administered 5-HT 3 antagonists was administered before and after chemotherapy. Granulocyte colony stimulating factor was administered to treat neutropenic events; however, prophylactic granulocyte colony stimulating factor and prophylactic antibiotics were not allowed in patients who had experienced a neutropenic event in the previous cycle.
Dose modifications
Dose modifications were done according to the study protocol. The next treatment cycle was initiated only when the neutrophil count was 1500/lL or greater and the platelet count was 100,000/lL or greater. Treatment was delayed in the event of grade 3/4 nonhematologic toxicities until the toxicities were resolved to grade 1 or lower. The doses of docetaxel and oxaliplatin were reduced by 25 % of the initial doses for related grade 3 toxicity or for the second occurrence of the same grade 2 toxicity. The dosage of S-1 was reduced by 20 mg/day for related grade 3 toxic effects or for the second occurrence of the same grade 2 toxicity. The doses of docetaxel and oxaliplatin were reduced by 50 % of the initial dose for related grade 4 toxicity, for the second occurrence of the same grade 3 toxicity, or for the third occurrence of same grade 2 toxicity. The dosage of S-1 was reduced by 40 mg/day for related grade 4 toxicity, for the second occurrence of the same grade 3 toxicity, or for the third occurrence of the same grade 2 toxicity. Treatment was discontinued if, despite the dose reduction, the same toxicity occurred for a fourth time at grade 2, a third time at grade 3, or a second time at grade 4. In addition, if the toxicity had not improved to grade 0 or grade 1 after 3 weeks, the patient was removed from the study. The dose reduction was maintained in subsequent cycles.
Response and toxicity evaluation
The response to therapy was assessed by radiological evaluation of any measurable lesion every two cycles based on RECIST version 1.0 [15] using three-dimensional computed tomography, and was determined by an independent response review committee. Confirmation of all complete and partial responses was required 4 weeks later. After discontinuation of the study treatment, patients were followed up every 3 months until disease progression or death.
Toxicity was evaluated and recorded according to version 3.0 of the Common Terminology Criteria for Adverse Events of the National Cancer Institute. All of the patients who received at least one dose of treatment were included in the toxicity assessment. For the toxicity analysis, the data indicating the worst toxicity for each patient from all of the chemotherapy cycles were used.
Statistical analysis
According to Simon's optimal two-stage design [16] , 38 patients were required for enrollment to test the null hypothesis that the true ORR is 20 % versus the alternative hypothesis that the true ORR is at least 45 %, at a significance level of 0.05 with a power of 90 %. If five or more responses were observed among 16 patients in the first stage, the study was continued with 22 additional patients included. As the drop-out rate was assumed to be 10 %, the number of patients necessary for recruitment into the study was calculated to be 43.
The intention-to-treat (ITT) population included all of the patients, and the per-protocol (PP) population excluded those patients who received treatment for less than 6 weeks for reasons other than disease progression or death or who received less than 50 % of the anticipated treatment during the first 6 weeks of the trial.
The response and toxicity data were described using simple descriptive statistics. PFS was calculated from the first day of treatment until the first day of documented disease progression or death from any cause. PFS was censored at the date of the last follow-up visit for the patients who were still alive and had no documented disease progression. OS was calculated from the first day of treatment until the day of death. The response duration was defined as the time from the first day of a documented partial or complete response until the documented date of disease progression. PFS and OS were estimated using the Kaplan-Meier method.
Results
Patient characteristics
From September 2007 to May 2009, 44 patients who met the inclusion criteria were enrolled in this study. The demographic and pathologic characteristics of the patients are described in Table 1 . The median age was 54.5 years
(range 25-69 years). Thirty-two patients (72.7 %) were male, and only one patient (2.3 %) had an ECOG PS of 2. All patients had metastatic disease. Thirty-four patients (77.3 %) had an initial diagnosis of metastatic disease, and ten patients (22.7 %) had recurrent gastric cancer after curative surgery. Twenty-seven patients (61.4 %) had poorly differentiated cancers, and the commonest metastatic sites were distant lymph nodes (80.1 %), the peritoneum (43.2 %), and the liver (27.3 %). The median number of metastatic organs was 2 (range 1-4).
Treatment delivery
In total, 340 treatment cycles were administered to 44 patients, with a median of eight cycles (range 1-36 cycles) per patient. One patient had to discontinue use of docetaxel because of grade 4 neutropenia and received oxaliplatin and S-1 doublet therapy for the remaining eight of 13 cycles. Five patients received the doublet of docetaxel and S-1 after experiencing grade 3 peripheral neuropathy. Two patients did not complete the first cycle of chemotherapy: one patient died suddenly of abdominal hemorrhage due to hepatic tumor rupture caused by disease progression, and the other patient was lost to follow-up. Thirty-one patients (70.5 %) received six or more cycles of chemotherapy. 
Safety
Safety was assessed in 43 patients on the basis of 339 cycles; one patient who was lost to follow-up after receiving docetaxel and oxaliplatin on day 1 of the first cycle, was excluded. One patient died suddenly of abdominal hemorrhage due to hepatic tumor rupture on day 3 of the first cycle. The adverse events are listed in Table 2 . The commonest grade 3/4 hematologic toxicities were neutropenia (37.2 %) and leukopenia (27.9 %). Febrile neutropenia developed in six patients (14.0 %), all of whom recovered without complication. Nonhematologic toxicities were usually mild and manageable. Grade 3 toxicities with a frequency of 5 % or more included peripheral neuropathy and deep vein thrombosis. Grade 3 peripheral neuropathy was observed in six patients (14.0 %), five of whom continued with the study regimen without receiving oxaliplatin. The median age of the patients was 54.5 years (range 25-69 years).
ECOG Eastern Cooperative Oncology Group
Efficacy
Of the 44 patients, 40 were eligible for response evaluation. Four patients were not available for response evaluation: three were lost to follow-up, and one died of rupture of a metastatic liver mass before response evaluation. Tumor responses are summarized in Table 3 . There were three complete responses, 21 partial responses, 15 cases of stable disease, and one case of disease progression. The confirmed ORR was 54. At the time of analysis, 16 patients (36.4 %) were still alive with a median follow-up duration of 12.9 months (95 % CI 9.6-16.3 months). The median PFS was 7.6 months (95 % CI 6.2-9.0 months), and the median OS was 12.0 months (95 % CI 6.9-17.2 months), with a 2-year survival rate of 38.6 % (95 % CI 24.7-54.5 %) in the ITT population as shown in Fig. 1 .
Among the various clinical parameters, the response to treatment was the only prognostic factor that was identified in univariate and multivariate analyses.
Discussion
To the best of our knowledge, this is the first phase II study to evaluate the efficacy and feasibility of the DOS regimen as a palliative chemotherapy in patients with metastatic gastric cancer. The primary outcome was ORR, and the secondary outcomes were safety, PFS, and OS. The observed ORR was 54.5 % in the ITT population, with a CI confidence interval Phase II study of docetaxel, oxaliplatin, and S-1 therapy in patients with metastatic gastric cancer 583 median PFS of 7.6 months and a median OS of 12.0 months. Although this was a phase II study, these efficacy results were favorably comparable to those obtained using DCF as first-line chemotherapy for AGC [4] . That study reported an ORR of 37 %, a median TTP of 5.6 months, and a median OS of 9.2 months. The DCF regimen of the V325 study consisted of docetaxel at 75 mg/m 2 and cisplatin at 75 mg/m 2 on day 1 plus 5-FU at 750 mg/m 2 on days 1-5, every 3 weeks. The dose of docetaxel was lower in this DOS regimen than in the DCF regimen without sacrificing treatment efficacy. Moreover, the low dose intensity was translated into low incidences of grade 3/4 hematologic toxicities. Grade 3/4 neutropenia and febrile neutropenia were observed in 38.1 and 14.3 % of patients in this study, whereas the DCF regimen resulted in much higher occurrences of 82 and 29 %, respectively. Given that the major concern of three-drug regimens is severe toxicity, these findings suggest an advantage of the DOS regimen. Recently, a phase II study of neoadjuvant DOS chemotherapy was reported [17] . Although most patients had stage II or stage III disease, the ORR was 53.8 and the disease control rate was 100 % after three cycles of DOS therapy. Grade 3/4 neutropenia and febrile neutropenia were observed in 34.1 and 9.8 % of patients, respectively. These findings of efficacy and toxicity were comparable to those of the current study, and provide support for the feasibility of the DOS regimen.
Capecitabine in combination with docetaxel and oxaliplatin (DOX) is another regimen investigated for the treatment of gastric cancer. A 3-week DOX regimen consisting of docetaxel at 60 mg/m 2 and oxaliplatin at 100 mg/ m 2 on day 1 and continuous orally administered capecitabine at 1000 mg/m 2 daily yielded an ORR of 52.1 %, a median PFS of 6.9 months, and a median OS of 12.6 months [18] . When docetaxel at 50 mg/m 2 and oxaliplatin at 75 mg/m 2 were administered intravenously on day 1, and capecitabine at 2750 mg/m 2 was administered orally on days 1-7 every 2 weeks, the ORR, median TTP, and median OS were 59 %, 10.0 months, and 18.0 months, respectively [19] . Considering also our study, docetaxelcontaining triplet regimens demonstrated better treatment outcomes compared with those for doublets including platinum and fluoropyrimidine. Among docetaxel-containing triplets, the treatment outcomes for the DOS regimen in the current study are comparable to those for the DOX regimens described above. However, the DOS regimen showed more favorable toxicity profiles in terms of hand-foot skin (HFS) reaction, one of the commonest toxicities with capecitabine to limit the daily activity of patients. The frequency of grade 3 or higher HFS reactions was much lower with the DOS regimen compared with the DOX regimens (0 % vs 6-15 %).
Recently, a phase III study comparing oxaliplatin plus S-1 (SOX) with cisplatin plus S-1 in chemotherapy-naive patients with AGC reported that SOX was as effective as cisplatin plus S-1, with a favorable safety profile [20] . Patients assigned to the SOX group received oxaliplatin at 100 mg/m 2 on day 1, and S-1 at 80 mg/m 2 for 2 weeks, every 3 weeks. The SOX regimen resulted in an ORR of 55.7 %, median PFS of 5.5 months, and median OS of 14.1 months. Grade 3/4 neutropenia and febrile neutropenia were seen in 19.5 and 0.9 % of SOX patients, respectively. The ORR for DOS was similar to that for SOX, however, addition of docetaxel seemed to cause more hematologic toxicities. Considering these results, comparative clinical trials with DOS and SOX seem to be warranted to identify the role of docetaxel in combination with SOX.
The treatment was generally well tolerated by most patients. The commonest grade 3/4 adverse event was neutropenia (37.2 % of all patients), and the second commonest grade 3/4 adverse event was leukopenia (27.9 %). Six patients (14.0 %) experienced febrile neutropenia. Although peripheral neuropathy of any grade was observed in most patients (88.4 %), grade 3 peripheral neuropathy was observed in six of 11 patients who received nine or more cycles of chemotherapy. On the other hand, only grade 1 and grade 2 HFS reactions were observed. Few grade 3/4 nonhematologic toxicities were observed, including anorexia, diarrhea, stomatitis, and deep vein thrombosis. Possible explanations for the favorable toxicity profiles include the younger patient population, a good ECOG PS, and strict adherence to the guideline for dose reduction or delay. The median age in our study was 54.5 years, and all patients except one had a good ECOG Fig. 1 Kaplan-Meier estimates of progression-free survival (PFS) and overall survival (OS). CI confidence interval PS (0 or 1). In addition, treatment was interrupted in patients with grade 2 or higher toxicity. Dose modification or delay conducted strictly according to the study protocol might have reduced the chance of developing severer (grade 3/4) toxicities in subsequent cycles.
As expected, the administration of the DOS regimen was convenient for the patients. Unlike the 5-FU-based regimens that require intravenous infusion of 5-FU for 2 or 5 days, the DOS regimen requires only a 3 h infusion of docetaxel and oxaliplatin and oral administration of S-1. Most patients in this study had a good PS. Although it was deemed an unintended consequence, it might overestimate the efficacy and safety of the DOS regimen. So, a larger study in a more heterogeneous patient group with the DOS regimen is needed.
In conclusion, the DOS regiment is effective, relatively well tolerated, and convenient. It seems to have potential to be a reasonable therapeutic strategy. Therefore, a larger study is warranted to confirm the efficacy and safety of the DOS regimen in the treatment of metastatic gastric cancer.
